Biological and adjuvant therapies, new trends in oral cancer treatment

Biological and adjuvant therapies, new trends in oral cancer treatment

Editorial  

AUTHORS: Marcello Iriti^1* and Elena Maria Varoni²

                                                            

AFFILIATIONS: ¹Department of Agricultural and Environmental Sciences, Milan State University, Milan, Italy. ²Department of Biomedical, Surgical and Dental Sciences, Milan State University, Milan, Italy

 Download full text from http://oncodrugs.org/journal/current.php (PDF)

Protective Agents for Chemotherapeutic Drugs Induced -Renal Failure

Protective Agents for Chemotherapeutic Drugs Induced -Renal Failure

Editorial  

AUTHOR: Sivakumar J T Gowder

 AFFILIATION: Qassim University, College of Applied Medical Sciences, Buraidah, Kingdom of Saudi Arabia.

 CORRESPONDING AUTHOR: via Sivakumar J T Gowder, Qassim University, College of Applied Medical Sciences,  P.Box-6800, Buraidah -51452, Kingdom of Saudi Arabia; Tel: +966566873969;  Fax: +96663802268;   Email: sivakumargowder@yahoo.com  

Download full text from http://oncodrugs.org/journal/current.php (PDF)

Nanostrategies in the war against multidrug resistance in leukemia

Nanostrategies in the war against multidrug resistance in

leukemia

Review Article 

AUTHORS: Alphy Rose-James¹, TT Sreelekha¹, Suraj K. George^2*

AFFILIATIONS: ¹Laboratory of Biopharmaceuticals, Division of Cancer Research, Regional Cancer Centre, Thiruvananthapuram-695 011, Kerala, India. ²Dept. of Hematopathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA

 

* CORRESPONDING AUTHOR: Dr. Suraj Konnath George PhD. Dept. of Hematopathology. Division of Pathology and Laboratory Medicine. University of Texas MD Anderson Cancer Center. 1515 Holcombe Blvd, Houston, TX 77030, USA. Ph: 001-7137927692   Fax: 001-7137927273. Email: skonnath@mdanderson.org or surajrcc@gmail.com

 Abstract

Chemotherapy is the cornerstone of treatment for haematological malignancies. Despite innovative advances in the understanding of this complex disease, multidrug resistance (MDR) is still a major culprit for the treatment failure, especially in leukemia. Conventional combinatorial therapy is a major decoy to circumvent MDR, but those are frequently thwarted by the evolving intricacies of the cancer paradigm. The advent of nanomedicine has ushered a new era with striking pharmacokinetic drug properties far enough to combat MDR. Physicochemical elements such as co-encapsulation, drug influx, ratiometric drug loading, temporal sequencing on drug release, and selective targeting moiety have been better tailored within the nanotherapeutics to overcome MDR. This review focuses on a plethora of nanostrategies and nanoplatforms which have been developed so far to battle MDR in leukemia.

Download full text (PDF) from OncoDrugs

Nutritional therapy: multitarget agents to prevent multifactorial diseases

Nutritional therapy: multitarget agents to prevent multifactorial diseases

Editorial  

AUTHORS: Marcello Iriti^1* and Elena Maria Varoni²

 

AFFILIATIONS: ¹Dipartimento di Scienze Agrarie e Ambientali, Università degli Studi di Milano. ²Dipartimento di Scienze Biomediche, Chirurgiche e Odontoiatriche, Università degli Studi di Milano.

Donwload full text (PDF) from http://www.oncodrugs.og/journal

Promote your work. Submit an Author's Brief

Author's Briefs. If you have published an original peer reviewed article in any Open Access Journal you likely own the copyright of your article and you can adapt or modify your work to share and distribute it. You can resubmit your original article to OncoDrugs as a short version highlighting the most important findings of your original paper and of course, citing the original source. This Author's Brief will not be peer reviewed and it is your responsibility to not distort the interpretation of the findings of the original articles.

 

Author's briefs serves two main purposes:

i) for authors, to promote their work by providing a short friendly version of a sometimes long article. This will also increase the citation number of the original article since OncoDrugs will encourage to cite the original source.

ii) for readers to find an alternative short version of important findings. Readers will alway have the chance to read the original open access article for details.

Author's brief should be short versions of manuscripts published no more than 6 months before submission to OncoDrugs and will be published within 7-14 days at no cost. To ensure that the Author's brief is submitted by the original author(s), only submission coming from the same e-mail address of the corresponding author listed in the original article will be accepted. Authors that have recently moved to another institution should provide evidence of the new affiliations (e.g. institutional website) when submitting an Author's Brief.

http://www.oncodrugs.org/journal/iab.php

Introducing Fair Peer-review

The peer review process of scholar articles is currently far from ideal. The standard pre-publication peer review has been extensively critizised for several reasons including:

-  Being time consuming.

- Arbitrary decision sometimes not based on scientific grounds such as "the article is not for the audience of the journal"  or "we receive so many articles...".

- Conflicts of interest.

 

Due to the above reasons, post-publication peer review has been introduced to allow the publication of all scientific articles.

Although the system is new, it does not seems to has broad acceptance by the scientific community. One of the main reason is the growing pressure of institutions and grant agencies on scientist to publish their research in journals with the highest impact factor that are most of them peer-reviewed. The quality of articles published under the post-publication peer review system has been of concern.

 

The fair publication peer-review process introduced by OncoDrugs is aimed to:

- Allow all manuscripts to have a chance to be published and reduce the revision and publication time after acceptance:

 

1) All manuscript submitted to OncoDrugs will be reviewed by at least two experts in the field.

2) Depending on the reviewer's comments articles will be:

        i) accepted (as it is or with minor changes) or

        ii) reconsider for publication with extensive revision.

None of the articles will be rejected after the first round of revision. This will eliminate the time delay, when rejected articles are formatted for  resubmision to another journal and will give all authors the opportunity to improve their article to reach the minimum criteria for publication (originality, scientific value and quality)

3) The reviewer comments will be sent to the authors who will decide to address the critics and have the chance to resubmitt their work to OncoDrugs.

4) Each resubmission (with a detailed response to each reviewer) will be evaluated in house a member of the editorial board or external reviewers.

5) A final decision (accepted with minor changes or rejected) will be communicated to the authors within 2-3 weeks.

 

OncoDrugs

OncoDrugs  is a new online only peer reviewed journal that accepts  articles  from all disciplines related to oncology drugs and cancer biology.

OncoDrugs accepts different type of Articles

• Original Research Articles (Peer reviewed)
• Short Communications (Peer reviewed)
• Reviews & Minireviews (Peer reviewed)
• Methods & protocols (Peer reviewed)
• Perspectives (Peer reviewed)
• Educational Articles (Peer reviewed)
• Editorials  (Non Peer reviewed)
• Author's Brief (Non- Peer reviewed)

http://www.oncodrugs.org/journal